A recent study has uncovered how prior exposure to antibodies can prime macrophages, the immune cells responsible for engulfing harmful targets like cancer cells, to be more effective in subsequent attacks. Macrophages typically “eat” pathogens, cancer cells, or dying cells through a process called phagocytosis, which is triggered when they detect “eat-me” signals, such as immunoglobulin G (IgG) antibodies, on the target’s surface.
Researchers have developed a novel optogenetic tool, called optoFcR, to precisely control the activation of macrophages’ phagocytic receptors. This tool allowed them to explore how different levels of receptor activation influence the macrophages’ ability to attack future targets.
Surprisingly, they found that lower levels of initial activation were more effective at priming macrophages for stronger responses later on. This priming effect occurs through two distinct mechanisms: a short-term boost that enhances the speed and efficiency of phagocytosis, and a long-term response that involves changes in gene expression, making macrophages more effective over a span of days.
These findings suggest that macrophages “remember” previous encounters with IgG-coated targets and adjust their behavior accordingly. This discovery could have significant implications for improving antibody-based therapies, such as those used in cancer treatment, by enhancing the macrophages’ ability to clear cancer cells more effectively.